HEPA Hepion Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 12 March 2020 Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study

   EDISON, NJ / ACCESSWIRE / March 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, ", Hepion", )), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease

2. 19 February 2020 Anti-Fibrotic Activity of Hepion Pharmaceuticals' CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases

   CRV431 Decreases Collagen and Fibronectin Production from Multiple Cell TypesEDISON, NJ / ACCESSWIRE / February 19, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the

3. 12 February 2020 Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

   EDISON, NJ / ACCESSWIRE / February 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

4. 28 January 2020 Hepion's NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study

   EDISON, NJ / ACCESSWIRE / January 28, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion" or the "Company"), a biopharmaceutical company focused on the development of therapeutic drugs for the

5. 08 January 2020 Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference

   EDISON, NJ / ACCESSWIRE / January 8, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

6. 06 January 2020 Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs

   EDISON, NJ / ACCESSWIRE / January 6, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

7. 10 December 2019 Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

   EDISON, NJ / ACCESSWIRE / December 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

8. 09 December 2019 Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019

   EDISON, NJ / ACCESSWIRE / December 9, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

9. 03 December 2019 Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments

   University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion

10. 03 December 2019 Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

    EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

11. 03 December 2019 Kilmer Lucas Announces Agenda for BioTuesdays Pre-JPM Virtual Conference on December 10th

    CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual

12. 20 November 2019 Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease

    EDISON, NJ / ACCESSWIRE / November 20, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

13. 07 November 2019 Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019

    EDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

14. 07 November 2019 Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH

    CRV431 has Potently Reduced Fibrosis in all Experimental Models Tested To DateEDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the

15. 10 October 2019 World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director

    EDISON, NJ / ACCESSWIRE / October 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from

16. 03 October 2019 Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions

    Collectively, Company's Senior Management Team Has More Than 100 Years of Cyclophilin ExperienceEDISON, NJ / ACCESSWIRE / October 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company